Search research articles
Contact Us
Filters
Showing results (51-60 of 104) with videos related to
Page
of 11
Sort By:
British Journal of Clinical Pharmacology
|
August 29, 2025
Predicting potassium trajectories for risk monitoring in outpatients with heart failure, diabetes mellitus or chronic kidney disease
Camilo Scherkl, Jacob Grytzka, Marietta Rottenkolber, et al.
Journal of Clinical Pharmacology
|
May 29, 2007
Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis
David Czock, Franz Maximilian Rasche, Alexander Carius, et al.
Nephron. Clinical Practice
|
May 22, 2003
Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy
Franz Maximilian Rasche, Christoph Hubert Klotz, David Czock, et al.
British Journal of Clinical Pharmacology
|
September 8, 2018
Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided
Andrea Huppertz, Lars Werntz, Andreas D Meid, et al.
Critical Care Medicine
|
December 24, 2005
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis
Jan T Kielstein, David Czock, Timo Schöpke, et al.
British Journal of Clinical Pharmacology
|
January 12, 2013
Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters
Barbara Grün, Michael K Kiessling, Jürgen Burhenne, et al.
Antimicrobial Agents and Chemotherapy
|
April 7, 2010
Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration
Verena Hafner, David Czock, Jürgen Burhenne, et al.
Nutrients
|
November 11, 2022
Efficacy and Safety of a Personalized Vitamin D<sub>3</sub> Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
Sabine Kuznia, David Czock, Annette Kopp-Schneider, et al.
Clinical Pharmacology and Therapeutics
|
June 2, 2019
Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers
Andrea Huppertz, Christian Ott, Thomas Bruckner, et al.
European Journal of Clinical Pharmacology
|
February 16, 2017
Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics
Anna V Medem, Hanna M Seidling, Hans-Georg Eichler, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 104) with videos related to
Sort By:
Page
of 11
British Journal of Clinical Pharmacology
|
August 29, 2025
Predicting potassium trajectories for risk monitoring in outpatients with heart failure, diabetes mellitus or chronic kidney disease
Camilo Scherkl, Jacob Grytzka, Marietta Rottenkolber, et al.
Journal of Clinical Pharmacology
|
May 29, 2007
Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis
David Czock, Franz Maximilian Rasche, Alexander Carius, et al.
Nephron. Clinical Practice
|
May 22, 2003
Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy
Franz Maximilian Rasche, Christoph Hubert Klotz, David Czock, et al.
British Journal of Clinical Pharmacology
|
September 8, 2018
Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided
Andrea Huppertz, Lars Werntz, Andreas D Meid, et al.
Critical Care Medicine
|
December 24, 2005
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis
Jan T Kielstein, David Czock, Timo Schöpke, et al.
British Journal of Clinical Pharmacology
|
January 12, 2013
Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters
Barbara Grün, Michael K Kiessling, Jürgen Burhenne, et al.
Antimicrobial Agents and Chemotherapy
|
April 7, 2010
Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration
Verena Hafner, David Czock, Jürgen Burhenne, et al.
Nutrients
|
November 11, 2022
Efficacy and Safety of a Personalized Vitamin D<sub>3</sub> Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
Sabine Kuznia, David Czock, Annette Kopp-Schneider, et al.
Clinical Pharmacology and Therapeutics
|
June 2, 2019
Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers
Andrea Huppertz, Christian Ott, Thomas Bruckner, et al.
European Journal of Clinical Pharmacology
|
February 16, 2017
Definition of variables required for comprehensive description of drug dosage and clinical pharmacokinetics
Anna V Medem, Hanna M Seidling, Hans-Georg Eichler, et al.
Page
of 11